香港儿童新冠疫苗对奥密克戎住院保护效果估计
该研究采用检测阴性设计,纳入2022年4月至2024年2月香港两家公立医院1-17岁因急性呼吸道疾病住院的儿童,评估新冠疫苗对实验室确诊感染的疫苗有效性。结果显示,1-4岁儿童总体疫苗有效性为41%(23-56%),5-17岁为54%(10-66%),mRNA疫苗有效性更高,且无既往感染者有效性更高。
要点
- 1-4岁儿童接种疫苗对新冠住院的总体有效性为41%(23-56%)。
- 5-17岁儿童总体有效性为54%(10-66%),mRNA疫苗达82%(59-92%)。
- 无既往SARS-CoV-2感染者疫苗有效性高于有既往感染者。
核心结论
- SARS-CoV-2疫苗,尤其是mRNA疫苗,在香港奥密克戎变异株主导的两波疫情期间为儿童提供了针对COVID-19相关住院的实质性保护。
研究设计与样本
- 采用检测阴性设计,纳入2022年4月至2024年2月香港两家公立医院1-17岁因急性呼吸道疾病(症状出现≤5天)住院的儿童,共6308例。
- 通过条件 logistic 回归按日历时间(周)分层并调整潜在混杂因素,分别估计1-4岁和5-17岁儿童的疫苗有效性。
主要发现
- 两个年龄组中,无既往SARS-CoV-2感染者的疫苗有效性均高于有既往感染者。
临床怎么用
- 在奥密克戎变异株流行期间,建议儿童接种SARS-CoV-2疫苗,尤其是mRNA疫苗,以降低COVID-19相关住院风险。
- 对于有既往SARS-CoV-2感染史的儿童,疫苗保护效果可能较低,接种策略需综合考虑感染史。
局限性
- 研究仅纳入香港两家公立医院的住院儿童,外推性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed the effectiveness of SARS-CoV-2 vaccines against COVID-19-associated hospitalisation in paediatric patients in Hong Kong. METHODS: We conducted a test-negative design study in hospitalised children 1-17 years old admitted with recent-onset (≤5 days) acute respiratory illness in two large public hospitals in Hong Kong during successive SARS-CoV-2 epidemic waves between April 2022 and February 2024 dominated by the Omicron variant. We defined having been vaccinated as receipt of ≥1 SARS-CoV-2 vaccine dose within six months prior to hospitalisation, and for a sensitivity analysis, within twelve months of hospitalisation. Children who had only received one dose of vaccine and had no prior infection were excluded. We estimated VE against laboratory-confirmed SARS-CoV-2 infection separately for 1-4-year-olds and 5-17-year-olds, by conditional logistic regression stratified by calendar time (week) and adjusted for potential confounders. RESULTS: There were 6308 patients. The proportion of the vaccinated within six months of hospitalisation differed significantly between cases and controls in all strata of the assessed individual sociodemographic/health-related characteristics in the 5-17-year-olds, and in 1-4-year-olds who had a chronic medical condition. Overall, VE was moderate for 1-4-year-olds [41% (23-56%)] and for 5-17-year-olds [54% (10-66%)]. VE was higher in those who had received a mRNA vaccine: 87% (0-98%) and 82% (59-92%) compared with a lower VE for those who had received an inactivated vaccine: 39% (17-54%) and 30% (-19-58%), respectively for 1-4-year-olds and 5-17-year-olds although with a higher degree of imprecision in the VE for mRNA in 1-4-year-olds. In both age groups, VE was higher for those who had had no previous SARS-CoV-2 infection compared with for those who had had a previous infection. CONCLUSIONS: SARS-CoV-2 vaccines, particularly mRNA vaccines, provided substantial protection against paediatric COVID-19-associated hospitalisations in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant.
引用
- Okoli GN, Kwan MYW, Chan ELY, et al. Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study. Vaccine. 2026. PMID: 41579753. doi:10.1016/j.vaccine.2026.128262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。